בידוד של מיקרוגליה ראשונית של עכבר על ידי מיון תאים המופעלים מגנטית במודלים של בעלי חיים של Demyelination

Executive Industry Relevance

Efficient isolation of primary microglia from demyelinated mouse brain tissue enables precise investigation of innate immune responses in disease-relevant CNS models. This capability supports mechanistic de-risking and target validation for neuroinflammatory and demyelinating disease pipelines. High-purity microglial preparations facilitate translational continuity from discovery through preclinical research in neuroimmunology portfolios.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of microglial activation states and phenotypic heterogeneity in disease-relevant CNS tissue.
• Supports functional target validation by preserving molecular characteristics of microglia from pathological lesions.
• Facilitates mechanistic de-risking for neuroinflammatory targets by isolating primary cells from in vivo models.

Screening & Assay Development

• Provides validated primary microglia for downstream functional assays and compound screening.
• Improves assay reproducibility and standardization by delivering high-purity, viable cell populations.
• Enables quantitative flow cytometry readouts for cell identity and viability, supporting robust assay development.

Translational & Preclinical Research

• Aligns with disease-relevant models for translational biomarker discovery in demyelinating conditions.
• Maintains continuity from in vivo discovery to preclinical validation by preserving microglial molecular profiles.
• Supports risk-adjusted advancement decisions by enabling direct study of microglial responses in pathological CNS environments.

Pipeline & Workflow Integration

This protocol integrates into the discovery-to-preclinical continuum for neuroinflammatory and demyelinating disease research.

• Discovery Biology: Supports hypothesis testing on microglial activation and heterogeneity in CNS lesions.
• Screening: Delivers reproducible, high-purity microglia for functional and phenotypic assays.
• Analytics: Enables quantitative flow cytometry analysis of cell identity, viability, and population shifts.
• Translational Research: Preserves disease-relevant molecular features for biomarker and mechanistic studies.
• Enterprise Reuse: Establishes a standardized workflow for isolating primary CNS immune cells across models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in neuroimmune target validation and mechanistic studies.
• Operational Value: Streamlines cell isolation with lower equipment and expertise requirements.
• Strategic Value: Enhances go/no-go decision quality by enabling direct study of primary microglia from disease models.
• Portfolio Impact: Reduces late-stage biological risk and supports risk-adjusted prioritization in neuroinflammation pipelines.

Implementation Considerations

• Requires proficiency in microdissection and handling of CNS tissue under a stereomicroscope.
• Needs access to magnetic-activated cell sorting instrumentation and flow cytometry for validation.
• Demands cross-team standardization of tissue processing and gating strategies for reproducibility.
• Adaptation may be needed for different CNS regions or disease models to maintain cell purity and viability.
• Careful lesion identification and sample handling are critical to preserve molecular characteristics.

Biopharma FAQs